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AbstrAct
Pancreatic ductal adenocarcinoma (PDA) harbors an exceedingly poor prognosis, 
and is generally considered a therapy-recalcitrant disease due to poor response to 
conventional chemotherapy coupled with non-actionable genetic drivers (e.g. KRAS 
mutations). However, PDA frequently loses p16ink4a, thereby leading to deregulation 
of CDK4/6. Surprisingly, in established cell models and xenografts, CDK4/6 inhibition 
has a modest effect on proliferation and resistance develops rapidly. To determine 
if such weak response was an intrinsic feature of PDA, we developed primary 
tumor explants that maintain the tumor environment and recapitulate feuture of 
primary PDA. The CDK4/6 inhibitor PD-0332991 was highly efficient at suppressing 
proliferation in 14 of the 15 explants. In the single resistant explant, we identified 
the rare loss of the RB tumor suppressor as the basis for resistance. Patient-derived 
xenografts (PDXs) were developed in parallel, and unlike the xenografts emerging 
from established cell lines, the PDXs maintained the histoarchitecture of the primary 
tumor. These PDXs were highly sensitive to CDK4/6 inhibition, yielding a complete 
suppression of PDA proliferation.  Together, these data indicate that primary PDA 
is sensitive to CDK4/6 inhibition, that specific biomarkers can delineate intrinsic 
resistance, and that established cell line models may not represent an adequate 
means for evaluating therapeutic sensitivities.
INtrODUctION
Pancreatic ductal adenocarcinoma (PDA) has a poor 
prognosis, with 5-year overall survival of approximately 
6% [1-4]. PDA is often diagnosed at a late stage, at which 
point a curative resection is no longer possible and the 
approved systemic therapies have a relatively modest 
impact on survival. Despite recent introduction of more 
effective chemotherapy regimens including FOLFIRINOX 
and combination of gemcitabine with Nab-paclitaxel, 
veritably all patients with advanced disease ultimately 
progress [5, 6]. The only approved targeted therapy, 
erlotinib in combination with gemcitabine, has added 
approximately 4 weeks to patient’s overall survival, while 
other targeted agents including MEK, PI3K and mTOR 
inhibitors, have failed to demonstrate any efficacy in 
clinical studies [6-8]. Thus, there is an urgent and unmet 
need to develop rational, targeted approaches for the 
treatment of pancreatic cancer. 
Genetic analysis of PDA has defined multiple 
oncogenic events that drive the initiation and progression 
of disease [9, 10]. Approximately 90% of pancreatic 
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cancers are driven by KRAS, while the loss of the TP53 
and SMAD4 tumor suppressors occurs in a large fraction 
of tumors. Unfortunately, these genetic events remain 
largely non-actionable due to the lack of drugs that 
selectively target these oncogenic events. An additional 
signature genetic/epigenetic event in PDA is the loss or 
silencing of the tumor suppressor CDKN2A [11]. Based 
on genetic analysis, mutation or homozygous deletion 
of CDKN2A occurs in ~50% of tumors, and epigenetic 
silencing is also frequently observed. Thus, the vast 
majority of PDA cases have functional loss of this tumor 
suppressor [8, 12]. 
The CDKN2A gene encodes the p16ink4a protein, 
which is a potent physiological inhibitor of CDK4/6 
[13]. During cell cycle progression, CDK4/6 is activated 
downstream of multiple signaling cascades, and is required 
to initiate the phosphorylation of RB and subsequent 
entry into S-phase [14, 15]. The levels of p16ink4a are 
stimulated during specific stresses, leading to a blockade 
of proliferation and inducing features of senescence [13]. 
In particular, p16ink4a serves as a critical mediator of 
oncogene-induced senescence driven by KRAS mutation; 
therefore, there is strong selective pressure for its loss in 
PDA [16, 17]. Consequently, it is believed that the loss of 
p16ink4a is a key hallmark of RAS driven tumors and is 
frequently observed in a host of tumors with deregulation 
of the KRAS/RAF oncogenic singnaling pathway 
including non-small cell lung cancer, melanoma and 
colorectal cancer, in addition to PDA [18-20].
Since p16ink4a functions as an inhibitor of CDK4/6, 
it would be anticipated that this cell cycle regulated 
kinase family would be an important and actionable target 
in PDA. Over the last several years, drugs specifically 
targeting CDK4/6 have been developed [21, 22]. Presently, 
three highly-specific agents are now amenable to clinical 
use (PD-0332991, LEE-011, and LY2835219). These 
agents induce cell cycle arrest and delay progression/
proliferation in tumor models [23-25]. This has been 
observed across a host of models and disease indications, 
including leukemias, breast cancer, and pediatric tumor 
types [21]. Surprisingly, in work published by several 
groups, single agent CDK4/6 inhibition had a particularly 
weak effect in models of pancreatic cancer [26-28]. Given 
the genetics of the disease, we sought to use patient-
derived models to better delineate the significance of 
CDK4/6 inhibition in the treatment of PDA.
rEsULts
Established models of PDA have a relatively weak 
response to cDK4/6 inhibition
In order to evaluate the response to CDK4/6 
inhibition, several well-established PDA cell lines were 
employed. Treatment with 1 µM PD-0332991 resulted 
in a modest suppression of proliferation, as measured 
by 5-bromo-2deoxyuridine (BrdU) incorporation, in 
established pancreatic cancer cell lines at 24 hours of 
treatment (Figure 1A). In these same cell lines, crystal 
violet staining after 7 days of treatment demonstrated 
variable inhibition of tumor cell growth amongst the 
PDA established lines, with the PANC1 line appearing 
relatively sensitive to CDK4/6 inhibition and the MIA-
PACA2 line appearing relatively resistant (Figure 1B). 
Interestingly, BrdU incorporation in cell lines treated 
with PD-0332991 over a span of 2 weeks demonstrated 
proliferation in the presence of the agent, suggesting 
a durable response is not achieved in these models and 
there is rapid progression to a resistance (Figure 1C). 
To determine if this phenotype was selective to cells in 
culture, PL-45 and PL-5 xenografts were developed. The 
mice were treated with PD-0332991 via oral gavage. The 
treatment with PD-0332991 did elicit suppression of tumor 
growth in PL-5 xenografts, with tumor volume in the 
treatment group significantly lower than that of controls 
(p < 0.0001). However, the suppression of residual 
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Figure 1: CDK4/6 inhibition yields modest efficacy in established models of PDA: A. Representative plots of BrdU 
incorporation in established PDA cell lines treated with PD-0332991 (1 μM) versus control (left panel). Quantification by flow cytometry 
of BrdU incorporation between control and PD-0332991 treated established cell lines (right panel). b. Crystal violet staining of established 
PDA cell lines after 7 days of treatment with control vs. PD-0332991 (upper panel). Photomicrographs of PDA cells in culture after 7 
days of treatment with control vs. PD-0332991 (bottom panel). c. Representative BrdU incorporation after 24 hours and after 2 weeks of 
treatment with PD-0332991. D. H&E and Ki-67 staining of established PDA cell line xenografts treated with control and PD-0332991. 
Quantification of Ki-67 staining in established PDA cell line xenografts treated with PD-0332991 and control. 
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tumor proliferation was relatively limited and even in the 
presence of daily dosing, a proliferative index of 79.6% 
in PL-5 xenografts and 40.6% in PL-45 xenografts was 
observed (Figure 1D). Together, these data in established 
models is consistent with recently published studies that 
suggests that monotherapy with CDK4/6 inhibitors may 
not be particularly effective in PDA [26-28]. 
Explants cultures recapitulate the diversity of 
PDA
Many established cell lines have experienced 
selection for growth in culture, which is known to 
selectively perturb cell cycle regulatory mechanisms 
[29]. Furthermore, the desmoplastic architecture of PDA 
contributed by neighboring stromal cells is known to be 
particularly important for its biology [30, 31]. Therefore, 
we sought to develop a primary tumor explant model as a 
means to accurately recapitulate key features of PDA. The 
protocol used here was based on prior work with breast 
cancer specimens [32]. Fresh surgical tissue, not required 
for diagnosis, was dissected into approximately ~1 mm3 
sections. These were cultured on a semi-solid support from 
0-192 hours, during which time drugs could be applied. 
Explant cultures where then removed, fixed, and stained 
for relevant markers. After the establishment of this 
methodology, 15 unselected, consecutive PDA specimens 
were studied as explants (Figure 2A). The clinical and 
histopathological data of the subjects are summarized 
in Supplemental Figure 1. All explants retained tissue 
architecture and degrees of cellularity comparable to 
that observed in the tumor section obtained for clinical 
pathologic evaluation (Figure 2B). Morphological and 
architectural integrity of tissues was maintained in tumor 
samples for up to 192 hours of culture (Supplemental 
Figure 2A). The proliferative index was assessed by Ki67 
immunostaining on day 1, 4, 6 and 8. The percentage 
of proliferating cells was stable across all time points, 
without a significant decrease up to 192 h (Supplemental 
Figure 2A). The number of apoptotic cells, visualized 
using cleaved caspase 3 staining also did not change 
significantly over time (Supplemental Figure 2A). The 
level of key molecular markers (p16ink4a, p53, EGFR) 
in the pathogenesis of PDA were evaluated in both 
primary tumor and explant, with representative staining 
between the surgical specimen and the cultured explants 
as shown (Figure 2B). P16ink4a loss or weak expression 
was seen in 14 of 15 cases (93%); strong p16 expression 
was seen in only one case (Case #5; Figure 2B). The 
TP53 tumor suppressor gene is frequently inactivated 
in PDA, with approximately 50% of these carcinomas 
showing intragenic mutation. Strong nuclear labeling 
for the p53 protein, which correlates with mutation 
stabilizing p53 protein, was present in 67% of primary 
tumors and corresponding explants cultures (Figure 2C). 
Strong membranous EGFR expression (score 3+), which 
stimulates downstream MAPK and PI3K/AKT signaling 
cascades to influence cell proliferation and metastasis 
[33], was seen in 5 of 15 (33.3%) of primary tumors and 
explants cultures. These findings demonstrate that ex 
vivo explants maintain the overall biomarker phenotype 
of the tumor. Given the theoretical possibility of high 
intra-explant variability, we evaluated six explant cases 
from duplicate and triplicate culture wells at 48 hours. As 
shown in Supplemental Figure 2B, there was significant 
concordance between multiple explants from a given 
case. To determine if the explant cultures retained the 
same proliferative nature of the primary tumor, Ki67 
was evaluated in parallel. Among primary tumors, a 
range from 21 to 89.5% of Ki67 positive tumor cells 
was observed (Figure 2C). There was a strong positive 
correlation in Ki67 index between the original tumor and 
the corresponding explanted tissue in all cases (R2 = 0.97, 
p < 0.001). These data indicate that the ex vivo explants 
retained the proliferative potential similar to that of the 
primary tumor. 
CDK4/6 inhibition has potent activity in patient 
explants
Preservation of tissue architecture, viability and 
molecular phenotype suggested that treatment of explant 
cultures with therapeutic agents could reveal sensitivities 
that would be concordant with the primary tumor. In 
PDA explants, treatment with PD-0332991 showed 
profound suppression of Ki67 staining (Figure 3A and 
3B). This effect was specific to the drug and was not 
observed in tissues treated with DMSO (vehicle) for the 
same period or with gemcitabine (Supplemental Figure 
3A). Interestingly, there was some heterogeneity in the 
response to PD-0332991. Specifically, 13 of the 15 cases 
exhibited a greater than 5-fold suppression of Ki67 upon 
exposure to PD-0332991, and post-treatment Ki67 index 
below 7% (Figure 3B). In contrast, one case maintained a 
Ki67 index of 16.5% post-treatment, in spite of a greater 
than 5-fold reduction (case #7), and one case showed no 
reduction in Ki67 staining (case #5). Of note, the response 
to PD-0332991 did not depend on p53 status but was 
specific to the tumor cells, since lymphocytes present 
within the explants effectively responded as evidenced 
by suppression of Ki67 (not shown). Thus, the failure to 
respond to PD-0332991 appears to be a consequence of 
tumor-specific genetic events, and not due to distinctions 
in intrinsic drug sensitivity of a given individual. Since 
preclinical data suggest that an intact RB pathway is 
required for the cytostatic response to PD-0332991 [34-
37], we further investigated the activation status of the 
RB pathway by immunohistochemical stains. Tumors 
that are RB deficient expressed exceedingly high levels 
of p16ink4a with high Ki67 proliferation index [13, 32]. 
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Figure 2: Primary tumor explants recapitulate multiple biological features of the disease: A. Schematic representation of 
the explant approach. b. Representative hematoxylin/eosin, EGFR, p53 and Ki67 staining between surgical specimens and tumor explants. 
c. Table summarizing the status of EGFR, p16, p53, RB and Ki67 index for the cases analyzed. D. Quantification of Ki67 staining from 
matched explant and surgical specimens demonstrating concordance. 
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Both the primary tumors and explants were stained for 
p16ink4a and RB. Within the cohort of evaluated cases, 
only one case exhibited high levels of p16ink4a and low 
RB (Case #5; Figure 3C). RB and p16ink4a expression 
was conserved between the primary tumors and the 
explants. These data indicate that the vast majority of PDA 
is responsive to PD-0332991 and only the infrequent loss 
of RB is associated with lack of response.
suppression of tumor growth in patient derived 
xenografts
Though tumor explants provide a striking 
recapitulation of the primary tumor, we sought to 
complement this approach with patient-derived xenografts 
to obtain in vivo data over a longer treatment period. In this 
model, fragments of primary tumor are subcutaneously 
implanted in NSG mice, allowing the tumors to grow and 
Figure 3: Tumor explants exhibit sensitivity to PD-0332991: A. Representative staining of Ki67 in drug-treated explants that 
exhibited significant response or lack of response (bottom panel) to PD-0332991 treatment (1 uM). B. Response to PD-0332991 across 
all explant cases evaluated. C. Representative staining for RB and p16ink4a in cases that responded (left panel) or did not respond (right 
panel) to PD-0332991.
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subsequently passaged into other NSG mice for expansion 
into treatment cohorts (Figure 4A). Unlike the PL-45 or 
PL-5 xenografts that harbor little tissue architecture 
reminiscent of PDA, the three patient-derived xenograft 
exhibited histologic architecture remarkably similar 
to their tumor of origin (Figure 4B). Treatment of the 
cohort with PD-0332991 resulted in marked suppression 
of tumor growth and in some cases a reduction in tumor 
volume (Figure 4C). Analysis of the tissue treated with 
PD-0332991 revealed complete suppression of Ki67 
across all three PDX cohorts (Figure 4D). This profound 
anti-proliferative effect on Ki67 was not seen in the PDX 
cohort treated with gemcitabine similar to the observations 
in explant culture (Supplemental Figure 3B). Each tumor 
had a low baseline of apoptosis, as observed with cleaved 
caspase 3, and PD-0332991 either had no effect or elicited 
a slight increase in tumor cell turnover (Figure 4E). 
Together, these data indicate that CDK4/6 suppression 
is particularly effective in limiting the proliferation of 
patient-derived models of resectable disease.
DIscUssION
Treatment of PDA continues to present a significant 
challenge and in spite of multiple preclinical studies there 
has been only modest improvement in survival, with the 
principle gains coming from cytotoxic chemotherapies [1]. 
The vast majority of preclinical studies supporting drug 
development are carried out in established cell line models 
grown in culture or as xenografts. While facilitating rapid 
analysis, these models are not entirely representative of 
PDA. Many of these models, as shown here, grow very 
rapidly in cell culture and correspondingly produce 
xenografts with higher Ki67 indices than those reported 
in clinical PDA samples. The average Ki67 index in 
primary PDA is ~30% and the tumor exhibits an organized 
glandular architecture [38]. Additionally, the tumor is 
dominated by desmoplastic stroma that has recently 
emerged as a tumor suppressive feature of the disease 
though it also inhibits drug uptake [30, 39-41]. Despite 
the established models harboring genetic alterations that 
would be expected to confer substantial sensitivity to 
targeting CDK4/6, xenografts derived from established 
cell lines rapidly progress. This may reflect decades of 
selection for cell cycle deregulation in culture conditions. 
As result, high proliferation index and possibly cell cycle 
deregulation in these models can simply overwhelm 
cytostatic/targeted therapies through mechanisms that may 
not reflect primary tumor biology. While our study focused 
on CDK4/6 inhibition, cell cycle responses influence the 
activity of a range of targeted agents [42, 43], and this 
observation could be relevant to many targeted drug 
therapies.
It has become well accepted that tumors regulate 
the development of surrounding stroma through the 
induction of growth factor receptors and the production 
of their ligands [41, 44, 45], and that there is a degree 
of reciprocity involved in this communication, i.e., 
tumor stroma can influence tumor epithelial cells. The 
mutual interaction between tumor cells and surrounding 
environment appears particularly significant in PDA, 
where stromal cell promote tumor development and 
invasiveness but, in some cases, also limit rampant 
tumor cell growth [30, 46-48]. Thus, it is of importance 
to develop models that recapitulate these complex 
interactions. We employed two models that allowed us to 
study therapeutic efficacy from patient specimens: ex vivo 
tissue explants cultures and patient-derived xenografts. 
The histological features of both models are highly 
distinct from the fairly uniform collection of cells seen in 
xenografts established through injections of tumor lines 
such as PL-45 and PL-5. However, each of these models 
has intrinsic advantages/disadvantages. The explant model 
provides a window into the intact tumor of the patient. 
It fully retains human tumor-stroma interactions, which 
allows for studying the activity of anticancer drugs and 
small molecule inhibitors in the context of an individual 
patient’s tumor biology-in some ways reproducing the 
effect of performing serial biopsies to assess tissue 
response to therapy. In spite of the desirable features of 
the explant model, it does not recapitulate mechanisms 
of drug delivery, metabolism, and in vivo physiology. 
The PDX models employed accurately recapitulate the 
histological features of the pancreatic cancer from which 
they were derived and allow the study of tumor growth 
and inhibition over time. In the era of personalized 
medicine, these models could allow genetic alterations 
in tumor cells to be targeted within the context of their 
complex interactions with the stromal compartment.
Targeting cell cycle control is an attractive anti-
tumor strategy, with the goal of preventing disease 
progression. The vast majority of human tumors exhibit 
some form of cell cycle deregulation, allowing tumors 
to proliferate unabated. Multiple aberrations affect the 
G1/S transition, including the amplification of D1 cyclin, 
deletions and mutations of RB and/or downregulation of 
CDK4/6 inhibitor p16ink4a [49, 50]. All these events lead 
to loss of proliferative control, with p16ink4a inactivation 
being exceedingly common in PDA [3, 13, 51]. Thus, it 
was unexpected that multiple established pancreatic cancer 
cell models would exhibit a relatively weak response to 
pharmacological CDK4/6 inhibit. In contrast, all explants 
that retained RB protein and showed low p16ink4A 
staining exhibited decrease in Ki67 proliferation index 
upon treatment with the CDK4/6 inhibitor PD-0332991. 
While RB loss has not been previously reported in 
pancreatic cancer cell models, the data here demonstrates 
that in some PDA cases functional expression of RB is 
lost. These data also indicate that the analyses of p16ink4a 
and RB status can be used prospectively to evaluate the 
response to CDK4/6 inhibitors in clinical specimens, and 
suggests an approach for developing markers for targeted 
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therapies prior to clinical trials. Moreover, cytostatic 
response to PD-0332991 was confirmed in PDX models, 
lending further support to the possibility that CDK4/6 
inhibitors may have potent activity in PDA. 
A key question is whether the distinct response to 
PD-0332991 between established and patient-derived 
models reflects intrinsic PDA biology. While established 
models were initially developed from PDA lesions, 
some originated from metastatic disease, and most have 
been serially cultured for long periods of time, wherein 
mutations that enhance proliferation are progressively 
selected. It remains unclear if changes acquired during 
passaging in vitro mirror mutations occurring in primary 
tumor post chemotherapy and/or during progression to 
metastatic disease. The work herein demonstrates that 
our patient-derived models of PDA share remarkably 
similar biology to their pancreatic tumor of origin, and 
that in these models, CDK4/6 inhibition leads to potent 
suppression of tumor growth. Despite limited efficacy 
in established cell line models, this data suggests that 
CDK4/6 inhibitors should be considered for inclusion into 
emerging pancreatic cancer clinical trials. 
Figure 4: Patient-derived xenografts recapitulate primary tumor and demonstrate significant vulnerability to CDK4/6 
inhibition: A. Schematic representation of the patient-derived xenograft approach. B. Representative hematoxylin/eosin staining between 
surgical specimens and patient-derived xenografts. c. Representative staining of Ki67 in control and PD-0332991 treated PDXs. D. 
Quantitation of Ki67 in the indicated PDX. E. Tumor growth of PDXs, normalized to initial tumor volume, while treated with PD-0332991 
or control. F. Representative staining of cleaved caspase 3 in both control and PD-0332991 treated PDXs. 
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MAtErIALs AND MEtHODs
Cell culture, derivation and treatment
The established cell lines PL-45, MIA-PACA2, 
PL-5, PANC1, and CAPAN2 were cultured in DMEM 
supplemented with 10% FBS, as previously published 
[28]. Cells were treated with 1 µM CDK4/6 inhibitor PD-
0332991, with drug replenished every 72 hours. Acute and 
durable responses to PD-0332991, measured at 24 hours 
and 2 weeks respectively, were assessed by 5-bromo-2-
deoxyuridine (BrdU) incorporation and measured by flow 
cytometry. Following conclusion of treatment, PDA cell 
models were fixed in ice-cold 70% ethanol (in PBS) for 
2 hours at 4ºC. Fixed cells were incubated with 2 M HCl 
and 0.3 mg/ml pepsin for 30 minutes at room temperature 
and neutralized with 0.1 M sodium borate (pH 8.5) for 
2 minutes. Following neutralization, cells were washed 
with IFA buffer (10 mM HEPES [pH 7.4], 25 mM NaCl, 
4% fetal calf serum) and then incubated in IFA containing 
0.5% Tween for 10 min at room temperature. Cells were 
pelleted and re-suspended in FITC-anti-BrdU diluted in 
IFA buffer (1:10) (BD Biosciences, San Jose, CA) for 1 
hour at room temperature. After antibody incubation, cells 
were washed once in IFA and incubated for 10 min on 
ice in 0.5 ml of PBS containing 20 μg/ml PI and 40 μg/
ml RNase. Cells were then analyzed by FACSCalibur 
(BD Biosciences) instrument to determine PI (red) and 
FITC (green) staining for nuclear DNA and BrdU content, 
respectively.
Tissue preparation and explant cultures
PDA tumor tissue from resected surgical specimens, 
which was not needed for diagnostic purposes, was used. 
The collection of tissue was approved by the institutional 
review board (IRB). Tissues collected for explants 
culture were placed into 10 mL of complete explant 
culture medium for transport to the laboratory. Explant 
culture media consisted of RPMI 1640 base (Sigma) 
supplemented with 10% fetal calf serum (FCS). Antibiotic/
antimycotic solution was added to a final concentration of 
1 X (Sigma). Hydrocortisone (Sigma) was re-suspended 
in 95% EtOH and supplemented at a concentration of 
1mg/100ml media. Lastly, recombinant human insulin 
was added at a final concentration of 1mg/100ml media 
(Gibco). Tissues were maintained in this medium at 4ºC 
until processing. All source tissues were plated as explants 
within 12 hours. Under sterile conditions and one hour 
prior to tissue dissection, 1 cm3 hemostatic gelatin dental 
sponges (Vetspon, Novartis) were hydrated in explant 
culture media at 37ºC. While the sponges were hydrating, 
tissues were transferred to a 10 cm cell culture dish with 
10 ml complete explant media for dissection. Using a 
sterile scalpel and microdissection scissors, any apparent 
fat tissue was removed from the surface of the specimen 
and discarded. Samples were then cut into 1 mm3 pieces. 
Upon complete hydration of gelatin sponges, each was 
transferred to individual wells of a 12-well cell culture 
dish, and 2.5 ml of complete explant media was added 
to each well. One mm3 dissected specimen sections were 
chosen at random and placed on top of each sponge using 
sterile forceps. Tissues were placed near the edges of the 
sponge to allow for media perfusion in between tissue 
sections. Explant cultures were incubated at 37oC and 5% 
CO2.
Each treatment condition was examined with three 
pieces of tissue per sponge. Fifteen independent PDA 
cases were evaluated. Only 12 explant cultures were 
evaluated for response to gemcitabine due to limited 
tissue. Following plating, explants were allowed to recover 
in explant media for 24 hours. Explants were then treated 
for 48 hours with vehicle control (DMSO), a selective 
CDK4/6 inhibitor PD-0332991 (1 μM), or gemcitabine 
(20 nM). Explants were removed from culture, fixed and 
processed for immunohistochemical analyses. 
Histology and immunohistochemical stains
The original tumor tissue and the explant of the 
tumor tissue were fixed in 10% neutral-buffered formalin 
and embedded in paraffin. Four microm sections were 
stained with H&E for the histological evaluation. For 
immunohistochemical analysis four micron paraffin 
sections were prepared, deparaffinized in xylene, and 
rehydrated with graded ethanol. Antigen retrieval was 
performed by microwave pretreatment. The following 
antibodies were employed for the analysis: Ki67 (clone 
30-9, dilution, Ventana Medical Systems), p53 (clone DO-
7, dilution 1:100, DAKO), p16ink4a (clone E6H4, dilution 
1:50, MTM Laboratories), RB (clone 1F8, dilution 1:50, 
Thermoscientific), EGFR (clone 5B7 prediluted, Ventana 
Medical Systems) and cleaved caspase 3 (clone 5A1E, 
dilution 1:300, Cell Signaling). All stains were performed 
using the BenchMark XT Slide Preparation System 
(Ventana Medical Systems).
Automated image analyses and scoring
Immunohistochemically stained primary tumor 
and explant slides were scanned using an Aperio 
ScanScope®CS instrument at 20X, (Aperio Technologies, 
Vista, CA, USA). Stains were quantified using analysis 
tools developed by Aperio. Nuclear algorithms were 
used to evaluate Ki67, p53 and RB stain; membranous 
and cytoplasmic algorithms were applied for EGFR and 
p16ink4a quantification, respectively. The mean staining 
intensity and percentage of staining cells were recorded 
for Ki67, p53, RB and p16ink4a stains. Immunolabeling 
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for p53 was interpreted as positive and predictive of 
TP53 mutations if >75% tumors cell showed strong 
positive staining. RB expression was scored as negative 
(cancer cells showed no staining while normal cells were 
positive), weak (mean staining intensity was less than 
adjacent normal cells), or strong (staining intensity was 
equal to adjacent normal cells). RB loss was defined as 
a score of either negative, or weak. For p16ink4a the 
staining was graded as 0 (no cells staining), 1+ (diffuse 
weak cytoplasmic expression or < 25% cell showing 
strong staining), 2+ (25% to 75% of cells with strong 
staining), and 3+ (> 75% cells showing strong staining). A 
3+ score was considered high expression. For EGFR the 
score (range 0-3) was reported. 
Patient-derived xenografts
NOD-SCID IL2Rgammanull (NSG) mice were 
maintained in a barrier facility under HEPA-filtered air 
with food and water available as desired. Food, water 
and cage bedding were sterilized prior to use. Mice were 
manipulated under sterile conditions during surgery. 
Animal experiments fulfilled National Institutes of 
Health and UT Southwestern requirements for humane 
animal care and were approved by the UT Southwestern 
Institutional Animal Care and Use Committee. 
Tumor tissue acquisition was performed under an 
Institutional Review Board (IRB) protocol approved at 
UT Southwestern Medical Center. Fresh tumor tissue was 
stored in sterile specimen cups and transported in RPMI-
1640 (Sigma-Aldrich, St. Louis, MO) on ice. The tumor 
specimens were dissected in 3 mm x 3 mm fragments and 
coated in Matrigel® basement membrane matrix (Corning 
Life Sciences, Bedford, MA). NSG mice were anesthetized 
with isoflurane and, once sedated, their flank was shaved 
and cleansed with 70% alcohol and betadine. A 1 cm 
incision was made through the skin and subcutaneous 
tissue. A tumor fragment was then implanted into the flank 
and the incision was closed with 4-0 Vicryl suture. Mice 
were monitored daily for 2 consecutive days after surgery 
with particular attention paid to animal distress, wound 
dehiscence and signs of infections. Thereafter, they were 
examined 2-3 times per week. Tumor size was assessed by 
measurement with calipers once a week. Tumor volume 
was approximated using measurements of tumor length 
and width with the formula: (length x (width2))/2. The 
mice were sacrificed and tumors were harvested once 
they reached a diameter greater than 1.5 cm. The tissue 
was frozen in liquid N2 as well as kept fresh in RPMI for 
passaging into a larger cohort of mice. All three patient-
derived xenografts were successfully passaged twice in 
order to develop a cohort large enough for treatment. 
cell line xenografts
Approximately 3.0x106 PL-45 and PL-5 cell lines 
were mixed with Matrigel® basement membrane matrix 
(Corning Life Sciences, Bedford, MA). Cells were 
injected subcutaneously into the flanks of NOD-SCID 
IL2Rgammanull (NSG) mice. Tumor progression was 
measured by calipers twice weekly and tumor volume was 
approximated using the formula: (length x (width2))/2.
Xenograft treatment
Treatment with PD-0332991 was performed on 
cohorts of at least 8 mice with tumors measuring between 
150 and 500 mm3. The mice were randomized to treatment 
or control arms. The treated mice received palbociclib 
via oral gavage at a dose of 125 mg/kg in pH 4 lactate 
buffer (50 mM) daily. Gemcitabine was administered 
by intraperitoneal injection at a dose of 50 µg/kg in 
phosphate buffered saline. The control mice received 
lactate buffer via oral gavage once daily. Tumor sizes were 
assessed daily using calipers to determine tumor volume 
as described above. Treatment lasted for 5-8 days, after 
which the mice were sacrificed and the tumors were fixed 
in 10% formalin for histologic and immunohistological 
analysis. 
Statistical analysis
All statistical analyses were performed using 
GraphPad Prism (GraphPad Software, Inc). Student’s 
t-test and Pearson correlation analyses were used and 
results with p < 0.05 were considered significant.
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